Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells

Journal of Surgical Research

Volumn 185, Issue 1, 2013, Pages 231-239

  Kim, Elizabeth M H ^a   Mueller, Kelly ^a   Gartner, Elaina ^a   Boerner, Julie ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cetuximab; Cisplatin; Dasatinib; EGFR; Src; Triple negative breast cancer

Indexed keywords

CETUXIMAB; CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRIPLE NEGATIVE BREAST CANCER;

CETUXIMAB; CISPLATIN; DASATINIB; EGFR; SRC; TRIPLE-NEGATIVE BREAST CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84886724906     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.06.041     Document Type: Article

References (31)

1. S.J. Isakoff Triple-negative breast cancer: role of specific chemotherapy agents Cancer J 16 2010 53
2. C.A. Hudis, and L. Gianni Triple-negative breast cancer: an unmet medical need Oncologist 16 Suppl 1 2011 1
3. C.K. Anders, and L.A. Carey Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer Clin Breast Cancer 9 Suppl 2 2009 S73
4. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747
5. A.D. Elias Triple-negative breast cancer: a short review Am J Clin Oncol 33 2010 637
6. P. Carotenuto, C. Roma, and A.M. Rachiglio Triple negative breast cancer: from molecular portrait to therapeutic intervention Crit Rev Eukaryot Gene Expr 20 2010 17
7. T.M. Brand, M. Iida, and D.L. Wheeler Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab Cancer Biol Ther 11 2011 777
8. M. Dimri, M. Naramura, and L. Duan Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior Cancer Res 67 2007 4164
9. K.L. Mueller, L.A. Hunter, and S.P. Ethier Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells Cancer Res 68 2008 3314
10. K.L. Mueller, Z.Q. Yang, and R. Haddad EGFR/Met association regulates EGFR TKI resistance in breast cancer J Mol Signal 5 2010 8
11. J. Nautiyal, P. Majumder, and B.B. Patel Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling Cancer Lett 283 2009 143
12. C. Li, M. Iida, and E.F. Dunn Nuclear EGFR contributes to acquired resistance to cetuximab Oncogene 28 2009 3801
13. B. Sen, and F.M. Johnson Regulation of SRC family kinases in human cancers J Signal Transduct 2011 2011 865819
14. A.J. Tevaarwerk, and J.M. Kolesar Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer Clin Ther 31 Pt 2 2009 2332
15. A.R. Tan, X. Yang, and S.M. Hewitt Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine, kinase inhibitor J Clin Oncol 22 2004 3080
16. M.E. Moynahan, T.Y. Cui, and M. Jasin Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation Cancer Res 61 2001 4842
17. J. Baselga, J. Albanell, and A. Ruiz Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 2005 5323
18. J. Baselga, P. Gomez, and A. Awada The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1) Ann Oncol 21 2010 viii96
19. L.A. Carey, H.S. Rugo, and P.K. Marcom TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer J Clin Oncol 30 2012 2615
20. H. Nogi, T. Kobayashi, and M. Suzuki EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer Oncol Rep 21 2009 413
21. M.C. Maa, T.H. Leu, and D.J. McCarley Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implication for the etiology of multiple human cancers Proc Natl Acad Sci USA 92 1995 6981
22. J.S. Biscardi, R.C. Ishizawar, and C.M. Silva Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer Breast Cancer Res 2 2000 203
23. J.S. Biscardi, A.P. Belsches, and S.J. Parsons Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells Mol Carcinog 21 1998 261
24. C.S. Pichot, S.M. Hartig, and L. Xia Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells Br J Cancer 101 2009 38
25. C. Lieu, and S. Kopetz The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy Clin Colorectal Cancer 9 2010 89
26. R.S. Finn, J. Dering, and C. Ginther Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 2007 319
27. F. Huang, K. Reeves, and X. Han Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection Cancer Res 67 2007 2226
28. L. Song, M. Morris, and T. Bagui Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival Cancer Res 66 2006 5542
29. Y.C. Lin, M.H. Wu, and T.T. Wei Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells Neoplasia 14 2012 463
30. J.G. Trevino, J.M. Summy, and D.P. Lesslie Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model Am J Pathol 168 2006 962
31. C.M. Perou, J.S. Parker, and A. Prat Clinical implementation of the intrinsic subtypes of breast cancer Lancet Oncol 11 2010 718